Jove
Visualize
Contact Us

Related Experiment Videos

Technology evaluation: rh lactoferrin, Agennix.

Jeanette H Andersen1

  • 1University Hospital of North Norway, Department of Medical Microbiology, Tromso N-9038, Norway. jeanettea@nfh.uit.no

Current Opinion in Molecular Therapeutics
|July 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of the histone deacetylase inhibitor potential of phorbazole analogues.

Bioorganic & medicinal chemistry·2025
Same author

Arctic Diatoms as a Source of Antibiofilm Compounds: Identification of Methyl 3-Hydroxyoctadecanoate and Pheophorbide <i>a</i>.

Biomolecules·2025
Same author

Exploring Tetraselmis chui microbiomes-functional metagenomics for novel catalases and superoxide dismutases.

Applied microbiology and biotechnology·2025
Same author

Community dynamics and metagenomic analyses reveal Bacteroidota's role in widespread enzymatic Fucus vesiculosus cell wall degradation.

Scientific reports·2024
Same author

Corrigendum: Four new suomilides isolated from the cyanobacterium <i>Nostoc</i> sp. KVJ20 and proposal of their biosynthetic origin.

Frontiers in microbiology·2023
Same author

Four new suomilides isolated from the cyanobacterium <i>Nostoc</i> sp. KVJ20 and proposal of their biosynthetic origin.

Frontiers in microbiology·2023
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Agennix is developing recombinant human lactoferrin for treating cancer, asthma, and wounds. This glycoprotein exhibits antibiotic, anti-inflammatory, and immunomodulatory properties and is in Phase II clinical trials.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Lactoferrin is a glycoprotein with known antibiotic, anti-inflammatory, and immunomodulatory activities.
  • Recombinant human lactoferrin (rhLactoferrin) is being developed as a therapeutic agent.

Purpose of the Study:

  • To evaluate the potential of rhLactoferrin in treating various medical conditions.
  • To investigate rhLactoferrin for applications in oncology, pulmonology, and wound healing.

Main Methods:

  • Development of recombinant human lactoferrin.
  • Ongoing Phase II clinical trials to assess efficacy and safety.

Main Results:

  • The abstract does not contain specific results from clinical trials.

Related Experiment Videos

  • The development of rhLactoferrin is progressing through clinical evaluation.

    • Conclusions:

    • rhLactoferrin shows promise as a therapeutic agent due to its multifaceted biological activities.
    • Further clinical investigation is warranted to establish its therapeutic value in cancer, asthma, and chronic wounds.